Cancer Cell

Article	Citations
Accelerated approvals: Early-phase success or premature authorization?	2019
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer	572
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton	559
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture	524
KIT as a therapeutic target in neuroendocrine prostate cancer	398
TAMing immunity through an unexpected source	393
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	386
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients	357
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer	331
Diet-microbiome interactions in cancer	328
Characterization of the generic mutant p53-rescue compounds in a broad range of assays	327
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas	317
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	295
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer	290
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition	288
Spatial profiling technologies illuminate the tumor microenvironment	278
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling	269
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target	267
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity	259
Bacteria in metastatic sites: Unveiling hidden players in cancer progression	256
B cell heterogeneity in cancer comes of age	251
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma	245
High endothelial venules in cancer: Regulation, function, and therapeutic implication	244
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer	239
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	237

T cell dynamism and immune-related adverse events	234
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation	234
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron	230
The aging lung microenvironment awakens melanoma metastases	229
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors	229
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer	227
Cancer vaccines	214
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion	211
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	208
A holistic view of cancer	206
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	206
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer	203
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer	203
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses	203
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer	201
Challenges in neoantigen-directed therapeutics	195
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells	193
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding	193
Immunosensitivity cuts across mismatch repair status in colorectal cancer	191
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?	188
A genetic portrait of metastatic seeds in lung adenocarcinoma	187
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma	185
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression	185
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma	184
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	183
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population	183
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade	177
Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer	175
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation	174
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis	169
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics	167
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation	161
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients	161
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors	160
Challenges and opportunities for modeling aging and cancer	158
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma	156
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer	155
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	154
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma	153
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy	153
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy	149
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	145
Dissecting bulk transcriptomes of diffuse large B cell lymphoma	143
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity	143
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade	141
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions	140
ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy	140
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes	138
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma	138
A path to translation: How 3D patient tumor avatars enable next generation precision oncology	135

The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma	135
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies	134
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers	134
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells	133
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis	132
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD	131
Midkine as a driver of age-related changes and increase in mammary tumorigenesis	129
Immune determinants of the pre-metastatic niche	129
Tumor-infiltrating lymphocytes: A new hope	127
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment	126
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	126
Integrated proteogenomic characterization of glioblastoma evolution	125
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	125
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring	123
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1	122
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells	120
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study	120
Multiplex computational pathology for treatment response prediction	117
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers	115
GDF15 research from bench to bedside	115
Firing up neutrophil anti-tumor immunity with cocktails	114
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma	111
The winner takes it all: Competition drives clonal selection in gliomagenesis	111
A circular RNA in neuroendocrine carcinomas	110
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma	110
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma	108
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy	108
New horizons at the interface of artificial intelligence and translational cancer research	106
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment	106
Tumors on different wavelengths	105
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma	105
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	105
Proteogenomic data and resources for pan-cancer analysis	105
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial	105
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	103
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma	103
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma	102
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	101
Lactobacillus reuteri—an old acquaintance takes on a new task in colorectal tumor surveillance	100
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma	100
GD2-CAR T cells in patients with osteosarcoma and neuroblastoma—it’s not only the T cells that matter	100
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma	99
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer	99
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models	99
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers	98
The promise and peril of KRAS G12C inhibitors	98
Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures	98
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	97
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer	97
Tumor heterogeneity	97
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	95
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer	95
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space	94
Plasma cell and cancer stem cell crosstalk in glioblastoma	94
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer	94
Stromal lipid species dictate melanoma metastasis and tropism	93
Stromal barriers to the abscopal effect	91
Bacteria and fungi: The counteracting modulators of immune responses to radiation therapy in cancer	89
Seed or soil: Tracing the immune subsets in metastatic tumors	89
Engineering myeloid cells for cancer immunotherapy	88
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy	87
High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer	86
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance	85
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis	85
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity	85
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	84
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers	84
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity	84
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	83
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	83
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow	81
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy	81
Tumor microbiome links cellular programs and immunity in pancreatic cancer	80
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient	80
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche	79
When immunotherapy meets surgery in non-small cell lung cancer	78
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer	78
Vascular characterization reveals immunomodulatory targets for brain metastases	78
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative	75
A first-in-class EGFR-directed KRAS G12V selective inhibitor	75

Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice	73
Identification of specific PP2A complexes involved in human cell transformation	72
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak	71
When essential metal elements become culprits—Cuproptosis in focus	71
Subclonal immune evasion in non-small cell lung cancer	71
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC	70
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site	69
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition	69
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression	69
A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma	69
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity	68
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding	67
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial	67
Genomic mapping of metastatic organotropism in lung adenocarcinoma	66
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	65
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression	65
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors	65
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	65
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy	64
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma	64
Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell	63
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer	63
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy	63
Overcoming melanoma therapy resistance with RAF-MEK and FAK inhibition	63
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade	63
Immune phenotypic linkage between colorectal cancer and liver metastasis	62
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance	62
Sex and cancer immunotherapy: Current understanding and challenges	62
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread	60
Immune memory shapes ovarian cancer recurrence	60
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma	60
Neutrophil-activating therapy for the treatment of cancer	58
Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice	58
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma	57
T cell engagers in solid tumors kick the door down	57
Insights into the co-evolution of epithelial cells and fibroblasts in the esophageal tumor microenvironment	57
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	56
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	56
Cooperative CAR targeting to selectively eliminate AML and minimize escape	56
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	55
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	55
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory	54
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment	54
Metabolic regulation of Cathepsin B in tumor macrophages drives their pro-metastatic function	54
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis	54
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)	53
Senescent alveolar macrophages promote early-stage lung tumorigenesis	53
Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors	53
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer	53
Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer	52
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	52
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma	52